Skip to main content

Table 2 Disease control, exacerbation burden and prevalence of severe asthma for 29,851 children aged 2–17 years with actively treated asthma from a nationwide cohort

From: Burden and unmet need for specialist care in poorly controlled and severe childhood asthma in a Danish nationwide cohort

 

Overall (N = 29,851)

Ages 2–5 years (N = 10,105)a

Ages 6–11 years (N = 9895)a

Ages 12–17 years (N = 9851)a

Asthma control

 Median annual SABA use

200 (100, 360)

300 (100, 500)

200 (100, 300)

100 (30, 250)

 High annual SABA useb

4750 (16%)

2566 (25%)

1558 (16%)

626 (6.4%)

  of which in specialist care

1320 (28%)

603 (23%)

515 (33%)

202 (32%)

Exacerbationsc

 Any exacerbation(s)

2353 (7.9%)

757 (7.5%)

895 (9.0%)

701 (7.1%)

  of which in specialist care

1354 (58%)

437 (58%)

530 (59%)

387 (55%)

  Number of exacerbations

1 (1, 1)

1 (1, 1)

1 (1, 2)

1 (1, 2)

 Moderate exacerbation(s)

616 (2.1%)

74 (0.7%)

182 (1.8%)

360 (3.7%)

  Number of exacerbations

1 (1, 1)

1 (1, 1)

1 (1, 1)

1 (1, 1)

 Severe exacerbation(s)

1807 (6.1%)

675 (6.7%)

739 (7.5%)

393 (4.0%)

  Number of exacerbations

1 (1, 1)

1 (1, 1)

1 (1, 1)

1 (1, 1)

 Near fatal exacerbation(s)

64 (0.2%)

30 (0.3%)

18 (0.2%)

16 (0.2%)

  Number of exacerbations

1 (1, 1)

1 (1, 1)

1 (1, 1)

1 (1, 1)

 Exacerbation-prone asthmad

1910 (6.4%)

699 (6.9%)

767 (7.8%)

444 (4.5%)

Possible severe asthmae

1430 (4.8%)

496 (4.9%)

642 (6.5%)

292 (3.0%)

  of which in specialist care

868 (61%)

316 (64%)

418 (65%)

134 (46%)

  1. GINA Global Initiative for Asthma, SABA Short-acting bronchodilator
  2. aStatistics presented: n (%); median (IQR)
  3. bDefined as > 400 annual doses of SABA for ages 0–11, > 600 for ages 12 and above
  4. cModerate exacerbations defined as redemption of oral prednisolone at 37.5 mg for at least 5 days, severe as hospitalization with an asthma diagnosis and near-fatal as admission to an intensive care unit with an asthma diagnosis. Number of exacerbations denote the median number of exacerbations per exacerbating child during the follow-up period
  5. dDefined as two moderate or one severe exacerbation(s) during the follow-up period
  6. eDefined as exacerbation-prone asthma with GINA Step 3 + 4 treatment for ages 0–11, exacerbation-prone GINA Step 4 or GINA Step 5 regardless of exacerbations for ages 12 and above